Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Lytix Biopharma AS ("Lytix") (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company, will release its first quarter 2024 results on Thursday, 30 May 2024. The results will be presented in a webcast with CEO Øystein Rekdal and CFO Gjest Breistein at 1:00pm CET.
We encourage you to send us questions in advance, to be addressed during the Q&A session. Please send your questions in an email to post@lytixbiopharma.com.
The presentation and subsequent Q&A session will be held in English and may be viewed live by registering here: https://forms.office.com/e/0djcLzR8Za
A recording of the presentation will be made available on https://www.lytixbiopharma.com/financial-reports after the presentation.
For more information, please contact:
Gjest Breistein, CFO: gjest.breistein@lytixbiopharma.com
About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.